Investigation of Antitumor Preventive Efficacy of E.coli and Ps.aeruginosa Phage Lysate - Derived Microbial Patterns in Mice
Abstract
Anti-tumor preventive efficacy of phage lysates of E.coli and Ps.aeruginosa has been studied in 2-3 months non-purebred male mice bearing transplanted Ehrlich carcinoma. Regimen of vaccinations was: 1) single – 0,25 ml phage lysates intraperitoneal injection 3 days before Ehrlich carcinoma inoculation (1x106 tumor cells); 2) 3 times vaccinations – 3, 6, and 9 days before inoculation of carcinoma; 3) 10 times vaccinations (during 10 days), before inoculation of carcinoma. Treatment efficacy was evaluated according to the indices of cancer growth (development of cancer tissue, cancer growth inhibition percent, lifespan and survival percent). Experiments have shown that single and 3 times preventive vaccinations inhibited tumor development and delayed malignant growth, while, 10 times permanent vaccinations had no effects on cancer growth. Cancer growth inhibition percent in single and 3 times vaccinated animals with E. coli phage lysate were 58% and 58.1%, and in case of Ps. aeruginosa – 50% and 56% on the average. Maximal lifespan of mice in control groups were 57 days on the average, while, by the 125th day of cancer growth, at single vaccination, the 17% of mice were alive, and in 3 times vaccinated mice the survival percent was 25%. At vaccinations with Ps. aeruginosa phage lysate it was 7% and 20% respectively. Anti-tumor potential of bacterial page lysates supposedly could be explained by immunoregulatory properties of the preparation stimulating innate immune responses of the organism.
Downloads
References
Gambashidze, K. G., Kalandarishvili, K. G., Khorava, P. A., Azaladze, T. N., Lasareishvili, B. G., Dzhaiani, E. G., & Tediashvili, M. I. (2012). Application of bacterial thermo-and phagelysates for suppression of malignant tumor growth in experimental studies: 2 comparative analysis of anticancer efficacy of thermo-and phagelysates of Ps. aeruginosa and E. coli. Georgian Medical News, (207), 50-56.
Garay, R. P., Viens, P., Bauer, J., Normier, G., Bardou, M., Jeannin, J. F., & Chiavaroli, C. (2007). Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. European journal of pharmacology, 563(1-3), 1–17. https://doi.org/10.1016/j.ejphar.2007.02.018
Hollow T.-Coley toxin’s hidden message//The Scientist, 2001,19-22.
Okamoto M. - Toll-like receptor signaling in anti-cancer immunity/ /J. Med. Invest., 2003, #50 (1-2:9).
Wang J. et al. - Peptidoglycan and lipoteichoic acid from Staphylococcus aureus induce tumor necrosis factor alpha, inteleukin 6 (IL-6), and IL-10 production in both T cells and monocytes in a human whole blood model// Inf. and Immunity, 2000, #68(7), 3965-3968.
Winter Ch., Nuss G. - Pyretogenic effects of bacterial lipopolysaccharide and the assay of antipyretic drugs in rats// Toxicology and Applied Pharmacology, 2012, #73, 9-15.
